Clinical Trial Detail

NCT ID NCT02631876
Title PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

ovarian cancer

peritoneum cancer

fallopian tube cancer

Therapies

Paclitaxel + Pegylated liposomal-doxorubicin

Gemcitabine

Topotecan

Mirvetuximab Soravtansine

Age Groups: adult

No variant requirements are available.